ATRIAL FIBRILATION OPPORTUNISTIC SCREENING AND STROKE (AFOSS).
NCT ID: NCT03589170
Last Updated: 2018-07-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
51410 participants
OBSERVATIONAL
2016-01-01
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Intervention: Characterize the ideal population for searching unknown atrial fibrillation and develop an understanding of actions that could be taken today to improve the diagnosis and management of AF.
C: Compare two large populations with and without opportunistic screening of AF about stroke incidence.
Outcome: MAIN OBJECTIVES
1. Compare two large populations with and without opportunistic screening of AF.
2. Relate the incidence of stroke episode with the AF diagnosis
3. Characterize the ideal population for searching unknown atrial fibrillation by making a multivariate predictor model.
4. Develop an understanding of actions that could be taken today to improve the diagnosis and management of AF.
5. Evaluate whether intervention results in improved outcomes
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Screening for Atrial Fibrillation (AF)-Potential Patients to Increase AF Detection Rate
NCT03313167
Screening for Atrial Fibrillation Among Older Patients in Primary Care Clinics
NCT03515057
A Study to Assess the Effectiveness of an Atrial Fibrillation (AF) Risk Prediction Algorithm and Diagnostic Test in Identifying Patients With AF.
NCT04045639
SCREENING AFTER STROKE - ATRIAL FIBRILLATION
NCT06675383
Screening for Atrial Fibrillation With Self Pulse Monitoring
NCT05818592
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It has been estimated that around one in five strokes are attributed to AF overall, and one in three strokes in people over the age of 80 are attributed to AF. AF-related strokes are associated with significant morbidity, mortality and healthcare costs, yet they are highly preventable. Unfortunately, AF is often undiagnosed or untreated when stroke occurs.
In addition, the absolute prevalence of undiagnosed atrial fibrillation in individuals over 60 years of age is 2.2%, equivalent to 20.1% of the overall prevalence of AF. This is higher than in the reports of other studies, which range from 0.49% to 1.7% when diagnosed by means of standard ECG, but lower than the AF incidence (30%) detected by continuous monitoring in patients with risk factors for stroke. The prevalence of AF in the community is probably underestimated, as a consequence of the failure to detect and diagnose it and may be responsible for an additional subset of the 25-40% of strokes of unknown cause. It has been suggested that asymptomatic AF represents a third of the total AF population, a result confirmed in pacemaker studies. Around thirty eight thousand Catalonian people over 60 year-old currently could suffer unknown AF, and consequently non-treated, and estimates project that between 1,350-2,475 stroke/year could be related to this untreated condition.
While the data confirm the evident age-related increase in the prevalence of persistent AF and demonstrate that hypertension is the most frequently associated cardiovascular risk factor together with the presence of cardiovascular disease there is not sufficient evidence regarding the procedures that may be most effective for achieving an early diagnosis of AF and reducing the associated risks. A significant proportion of people with AF are diag¬nosed by chance during health assessments carried out for other reasons, or due to having a stroke. There may be multiple reasons for under-diagnosis, including the fact that AF can be asymptomatic and a lack of awareness about the condition and its symptoms. There is considerable interest in developing AF screening programs
Opportunistic screening, where patients are checked for AF when they visit doctors for other reasons, is widely supported as a means to achieve higher rates of detec¬tion to enable early intervention. Screening for AF anyone \>65 years or at high risk of stroke has been recommended by Mention of European Society of Cardiology (ESC), Stroke Alliance for Europe (SAFE), European Heart Rhythm Association (EHRA), Royal College of Physicians of Edinburg (RCPE), World Healthcare Forum (WHF), European Primary Care Cardiovascular Society (EPCCS), Health Information and Quality Authority (HIQA), and AF-SCREEN. Currently, routine mass screenings are not carried out in any countries at a national level. Opportunistic screening was tested against routine screening by the SAFE study, which found that opportunistic screening improved on routine practice and out¬reach campaign in Spain\[23\] was found to have had little effect on diagnosis of previously undetected AF and it was concluded that opportunistic screening is thus a better strategy for early detection.
It is important to note that, for many patients with AF, the condition is often asymptomatic - or associated with minor symptoms that are ignored or unrecognized by patients - and some type of AF screening is needed. Until the new external devices can be used more widely, ECG combined with reviews of medical history will continue to be the most feasible noninvasive strategy for identifying individuals with AF in epidemiological studies. The key issue, however, is not which test is best for diagnosing AF or how to undertake an effective screening procedure, but it is rather the appropriate measurement of results and achieving optimal effectiveness.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
ECOLOGIC_OR_COMMUNITY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
People over 60 years of age
People over 60 years of age without previous known atrial fibrillation
Opportunistic atrial fibrillation screening
Opportunistic pulse palpation and/or ECG at least once a year when they visit doctors or nurse for other reasons.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Opportunistic atrial fibrillation screening
Opportunistic pulse palpation and/or ECG at least once a year when they visit doctors or nurse for other reasons.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jordi Gol Primary Health Research Institute
UNKNOWN
University Rovira i Virgili
OTHER
Catalan Institute of Health
OTHER_GOV
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jose Maria Alegret-Colomè, PhD
Role: STUDY_DIRECTOR
University Rovira i Virgili
References
Explore related publications, articles, or registry entries linked to this study.
Panisello-Tafalla A, Clua-Espuny JL, Gil-Guillen VF, Gonzalez-Henares A, Queralt-Tomas ML, Lopez-Pablo C, Lucas-Noll J, Lechuga-Duran I, Ripolles-Vicente R, Carot-Domenech J, Lopez MG. Results from the Registry of Atrial Fibrillation (AFABE): Gap between Undiagnosed and Registered Atrial Fibrillation in Adults--Ineffectiveness of Oral Anticoagulation Treatment with VKA. Biomed Res Int. 2015;2015:134756. doi: 10.1155/2015/134756. Epub 2015 Jul 1.
Clua-Espuny JL, Lechuga-Duran I, Bosch-Princep R, Roso-Llorach A, Panisello-Tafalla A, Lucas-Noll J, Lopez-Pablo C, Queralt-Tomas L, Gimenez-Garcia E, Gonzalez-Rojas N, Gallofre Lopez M. Prevalence of undiagnosed atrial fibrillation and of that not being treated with anticoagulant drugs: the AFABE study. Rev Esp Cardiol (Engl Ed). 2013 Jul;66(7):545-52. doi: 10.1016/j.rec.2013.03.003. Epub 2013 May 31.
Clua-Espuny JL, Panisello-Tafalla A, Lopez-Pablo C, Lechuga-Duran I, Bosch-Princep R, Lucas-Noll J, Gonzalez-Henares A, Queralt-Tomas L, Ripolles-Vicente R, Calduch-Noll C, Gonzalez-Rojas N, Gallofre-Lopez M. Atrial Fibrillation and Cardiovascular Comorbidities, Survival and Mortality: A Real-Life Observational Study. Cardiol Res. 2014 Feb;5(1):12-22. doi: 10.14740/cr324e. Epub 2014 Feb 27.
Clua-Espuny JL, Pinol-Moreso JL, Gil-Guillen VF, Orozco-Beltran D, Panisello-Tafalla A, Lucas-Noll J, Queralt-Tomas ML, Pla-Farnos R. [Primary and secondary cardiovascular prevention results in patients with stroke: relapse risk and associated survival (Ebrictus study)]. Rev Neurol. 2012 Jan 16;54(2):81-92. Spanish.
Clua Espuny JL, Dalmau Llorca MR, Aguilar Martin C; Grupo de Trabajo. [Characteristics of oral anti-coagulation treatment in high-risk chronic auricular fibrillation]. Aten Primaria. 2004 Nov 15;34(8):414-9. doi: 10.1016/s0212-6567(04)78925-8. Spanish.
Gimenez-Garcia E, Clua-Espuny JL, Bosch-Princep R, Lopez-Pablo C, Lechuga-Duran I, Gallofre-Lopez M, Panisello-Tafalla A, Lucas-Noll J, Queralt-Tomas ML. [The management of atrial fibrillation and characteristics of its current care in outpatients. AFABE observational study]. Aten Primaria. 2014 Feb;46(2):58-67. doi: 10.1016/j.aprim.2013.06.003. Epub 2013 Sep 14. Spanish.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-ECO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.